Skip to search formSkip to main contentSkip to account menu

palonosetron

Known as: (3aS)-2-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-2,3,3a, 4,5,6-hexahydro-1H-benz[de]isoquinolin-1-one, Palonosetronum, palonosetron [Chemical/Ingredient] 
The active ingredient in a drug used to treat nausea and vomiting caused by cancer treatment. Palonosetron is a type of serotonin receptor antagonist… 
National Institutes of Health

Related topics

Related topics

10 relations
5 ML palonosetron 0.05 MG/ML Injection [Aloxi]Serotonin 3 Receptor Antagonists [MoA]netupitant / palonosetronnetupitant 300 MG / palonosetron 0.5 MG Oral Capsule [Akynzeo]

Narrower (3)

AloxiPalonosetron hydrochlorideRS 25259

Broader (3)

IsoquinolinesQuinuclidinesSerotonin Antagonists

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Radiation induced nausea and vomiting.
2014
2014
Comparative HPLC enantioseparation on substituted phenylcarbamoylated cyclodextrin chiral stationary phases and mobile phase effects.
2014
2014
Analgesic effects of palonosetron in the intravenous propofol injection
Background Propofol is a good induction agent, but it has the disadvantage of causing pain on intravenous injection. The… 
Review
2014
Review
2014
Serotonin type 3-receptor antagonists for chemotherapy-induced nausea and vomiting: therapeutically equivalent or meaningfully different?
Before the introduction of serotonin type 3–receptor (5-HT3) antagonists, nausea and vomiting were the most frequently reported… 
2012
2012
Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy
Introduction:  With repeated courses of chemotherapy, chemotherapy‐induced nausea and vomiting (CINV) becomes progressively more… 
2012
2012
Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study
ObjectivesPalonosetron is a novel 5-hydroxytryptamine3 (5 HT3) receptor antagonist, which has been shown to be superior to first… 
2011
2011
Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients
Lung cancer is the leading cause of cancer-related death for both men and women worldwide, and lung cancer also has the highest… 
Review
2009
Review
2009
Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist
Background: Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life… 
2008
2008
The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized…
PurposeThis clinical trial was conducted to evaluate the efficacy and safety of Palonosetron in preventing chemotherapy-induced… 
Review
2004
Review
2004
Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Despite the advance in supportive care that occurred with the introduction of selective serotonin subtype 3 (5-HT3) receptor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)